When failure should be the option.
作者信息
Petsko Gregory A
机构信息
Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA 02454-9110, USA.
出版信息
BMC Biol. 2010 May 21;8:61. doi: 10.1186/1741-7007-8-61.
Abstract
摘要
相似文献
1
When failure should be the option.当失败成为一种选择时。
BMC Biol. 2010 May 21;8:61. doi: 10.1186/1741-7007-8-61.
2
Adaptive clinical trials in tuberculosis: applications, challenges and solutions.结核病的适应性临床试验：应用、挑战与解决方案
Int J Tuberc Lung Dis. 2015 Jun;19(6):626-34. doi: 10.5588/ijtld.14.0988.
3
Genomics drugs in clinical trials.处于临床试验阶段的基因组学药物。
Nat Rev Drug Discov. 2010 Dec;9(12):988. doi: 10.1038/nrd1552-c1.
4
Trial watch: personalized medicines in late-stage development.试验观察：处于后期研发阶段的个性化药物
Nat Rev Drug Discov. 2014 May;13(5):324-5. doi: 10.1038/nrd4325.
5
Integrating dose estimation into a decision-making framework for model-based drug development.将剂量估计整合到基于模型的药物开发决策框架中。
Pharm Stat. 2018 Mar;17(2):155-168. doi: 10.1002/pst.1841. Epub 2018 Jan 10.
6
Know your target, know your molecule.了解你的靶点，了解你的分子。
Nat Chem Biol. 2015 Jun;11(6):368-72. doi: 10.1038/nchembio.1813.
7
Moving from an asthma pipe dream to a pipeline.从哮喘的空想迈向实际进展。
Nat Rev Drug Discov. 2012 Oct;11(10):737-8. doi: 10.1038/nrd3858.
8
A comparison of methods for adaptive treatment selection.自适应治疗选择方法的比较。
Biom J. 2008 Oct;50(5):767-81. doi: 10.1002/bimj.200710453.
9
Utility-based optimization of phase II/III programs.基于效用的II/III期试验方案优化
Stat Med. 2016 Jan 30;35(2):305-16. doi: 10.1002/sim.6624. Epub 2015 Aug 9.
10
The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.在药物早期研发中使用机制性生物标志物评估中枢神经系统候选化合物
Curr Opin Investig Drugs. 2010 Jul;11(7):795-801.
引用本文的文献
1
Genetic factors associated with reasons for clinical trial stoppage.与临床试验中止原因相关的遗传因素。
Nat Genet. 2024 Sep;56(9):1862-1867. doi: 10.1038/s41588-024-01854-z. Epub 2024 Jul 29.
2
Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-diseased tissue gene expression profiles in silico.通过计算机模拟评估肿瘤细胞系和患者来源的异种移植对肿瘤和非病变组织基因表达谱的重现性。
Cancer Rep (Hoboken). 2023 Sep;6(9):e1874. doi: 10.1002/cnr2.1874. Epub 2023 Aug 2.
3
Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-diseased tissue gene expression profiles .评估肿瘤和非疾病组织基因表达谱在癌细胞系和患者来源异种移植中的重现性。
bioRxiv. 2023 Jun 15:2023.04.11.536431. doi: 10.1101/2023.04.11.536431.
4
How to build a tumor: An industry perspective.如何构建肿瘤：产业视角。
Drug Discov Today. 2022 Oct;27(10):103329. doi: 10.1016/j.drudis.2022.07.014. Epub 2022 Jul 28.
5
Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies as a Therapeutic Target for Rectal Cancer.基于基因表达特征逆转的药物重新定位确定[具体内容缺失]为直肠癌的治疗靶点。
Cancers (Basel). 2021 Oct 31;13(21):5492. doi: 10.3390/cancers13215492.
6
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.他汀类药物作为一种潜在的化疗药物：作为单一疗法、联合疗法及抗癌药物耐药性治疗的最新进展
Pharmaceuticals (Basel). 2021 May 16;14(5):470. doi: 10.3390/ph14050470.
7
Science's Response to CoVID-19.科学应对新冠病毒。
ChemMedChem. 2021 Aug 5;16(15):2288-2314. doi: 10.1002/cmdc.202100079. Epub 2021 Jun 22.
8
Overcoming cancer therapeutic bottleneck by drug repurposing.通过药物再利用克服癌症治疗瓶颈。
Signal Transduct Target Ther. 2020 Jul 2;5(1):113. doi: 10.1038/s41392-020-00213-8.
9
Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery.计算生物学和人工智能技术在癌症精准药物发现中的应用。
Biomed Res Int. 2019 Nov 11;2019:8427042. doi: 10.1155/2019/8427042. eCollection 2019.
10
After 50 Years of Heart Transplants: What Does the Next 50 Years Hold for Cardiovascular Medicine? A Perspective From the International Society for Applied Cardiovascular Biology.心脏移植50年后：心血管医学的未来50年将何去何从？来自国际应用心血管生物学学会的观点
Front Cardiovasc Med. 2019 Feb 14;6:8. doi: 10.3389/fcvm.2019.00008. eCollection 2019.
本文引用的文献
1
The devil's in the details.魔鬼在细节中。
Genome Biol. 2010;11(4):117. doi: 10.1186/gb-2010-11-4-117. Epub 2010 Apr 30.
Zotero 插件